Trials / Completed
CompletedNCT02886884
Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects
A Phase I/II, Randomized, Double Blind, Pilot Trial to Evaluate the Safety and Efficacy of Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Joshua M Hare · Academic / Other
- Sex
- All
- Age
- 21 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This is a 16 subject trial to demonstrate the safety of allogeneic hMSCs administered via infusion therapy for diabetic subjects with endothelial dysfunction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 20 million Allogeneic Mesenchymal Human Stem Cells | 1 single intravenous infusion |
| DRUG | 100 million Allogeneic Mesenchymal Human Stem Cells | 1 single intravenous infusion |
Timeline
- Start date
- 2017-10-20
- Primary completion
- 2019-08-26
- Completion
- 2020-09-03
- First posted
- 2016-09-01
- Last updated
- 2022-05-11
- Results posted
- 2022-05-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02886884. Inclusion in this directory is not an endorsement.